Media coverage about AtriCure (NASDAQ:ATRC) has been trending somewhat positive on Tuesday, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. AtriCure earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news coverage about the medical device company an impact score of 45.8356926659605 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of AtriCure (ATRC) opened at 20.00 on Tuesday. AtriCure has a 12-month low of $14.78 and a 12-month high of $25.18. The company’s 50-day moving average is $22.42 and its 200-day moving average is $21.34. The company’s market capitalization is $686.68 million.
AtriCure (NASDAQ:ATRC) last posted its earnings results on Thursday, July 27th. The medical device company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.05. AtriCure had a negative net margin of 19.56% and a negative return on equity of 19.56%. The firm had revenue of $45.23 million during the quarter, compared to analyst estimates of $44.15 million. During the same period last year, the firm posted ($0.26) earnings per share. AtriCure’s revenue for the quarter was up 14.0% compared to the same quarter last year. Analysts predict that AtriCure will post ($0.95) EPS for the current year.
ATRC has been the subject of several research analyst reports. Stifel Nicolaus reiterated a “buy” rating and set a $25.00 target price on shares of AtriCure in a research report on Sunday, July 30th. Needham & Company LLC reiterated a “buy” rating and set a $26.00 target price (up from $25.00) on shares of AtriCure in a research report on Friday, July 28th. BidaskClub lowered shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. TheStreet upgraded shares of AtriCure from a “d+” rating to a “c-” rating in a research report on Monday, May 15th. Finally, ValuEngine upgraded shares of AtriCure from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $25.00.
In related news, Director Elizabeth D. Krell sold 10,000 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $22.40, for a total value of $224,000.00. Following the completion of the sale, the director now directly owns 29,967 shares in the company, valued at $671,260.80. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 10.00% of the stock is owned by company insiders.
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.